Skip to main content
RT @RHEUMarampa: Tofa for RA by the grp of Dr. Atul Deodhar:
>Tofa(56%) vs. pbo(29.4%)-significant improvement in AS

sheila RHEUMarampa

2 weeks 4 days ago
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
RT @MeralElRamahiMD: Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint

Meral K. El Ramahi, MD MeralElRamahiMD

2 weeks 4 days ago
Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint of patients with inflammatory back pain in trying to determine if a patient has SpA! #ACR20 @RheumNow https://t.co/gwySNvfSH5
A Review of RA Studies at ACR: Dr. Janet Pope

Dr. Janet Pope reviews #0483, #0187, #1715, #0151 and #1736 presented at the 2020 ACR annual meeting.

Lifestyle and Risk of RA, Lupus: Dr. Janet Pope

Dr. Janet Pope reviews abstracts #1198 and #1473 presented at the 2020 ACR annual meeting.

RT @SituationRheum: 📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future

👉close surveillance ➡️ early det

Elizabeth Graef SituationRheum

2 weeks 4 days ago
📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI
RT @SituationRheum: And we're off! #ACR20 year in review

⭐️@philseo's #Vasculitis lecture⭐️

Take home lessons/

Elizabeth Graef SituationRheum

2 weeks 4 days ago
And we're off! #ACR20 year in review ⭐️@philseo's #Vasculitis lecture⭐️ Take home lessons/ remaining questions from GiACTA ⬇️ #ACRambassador https://t.co/7C9QxbUeNH
RT @SituationRheum: 📌More #Vasculitis pearls from #ACR20 Year in Review

#PEXIVAS in a nutshell ⬇️

#ACRambassa

Elizabeth Graef SituationRheum

2 weeks 4 days ago
📌More #Vasculitis pearls from #ACR20 Year in Review #PEXIVAS in a nutshell ⬇️ #ACRambassador https://t.co/PnoP7QIiYs
RT @DrBhana: from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reim

Suleman Bhana, MD DrBhana

2 weeks 4 days ago
from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives. #ACRambassador https://t.co/ARo762Vozp
RT @vksandhumd: Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador http

Vaneet K Sandhu, MD vksandhumd

2 weeks 4 days ago
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
RT @BharatKumarMD: Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with fi

Bharat Kumar BharatKumarMD

2 weeks 4 days ago
Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy
RT @vksandhumd: ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT

Vaneet K Sandhu, MD vksandhumd

2 weeks 4 days ago
ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT
RT @vksandhumd: Hypophosphatasia
- CPPD/chondrocal, enthesop'y, DISH, exostoses
- DDx of Low ALP: milk-alkali, Vit D int

Vaneet K Sandhu, MD vksandhumd

2 weeks 4 days ago
Hypophosphatasia - CPPD/chondrocal, enthesop'y, DISH, exostoses - DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM Rx - asfotase alpha- bone targeted replac't Rx #ACR20 #ACRambassador https://t.co/FJ1355MdKG
RT @SattuiSEMD: #ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall imp

Sebastian E. Sattui MD, MS SattuiSEMD

2 weeks 4 days ago
#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6
×